982397252	982397252	CD	B-NP	O
|	|	NNP	I-NP	O
RH	RH	NNP	I-NP	O
|	|	VBD	B-VP	O
74249195	74249195	CD	B-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
5433323	5433323	CD	B-NP	O
|	|	CC	I-NP	O
3/10/2002	3/10/2002	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Summary	Summary	NNP	I-NP	O
|	|	NNP	I-NP	O
Signed	Signed	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
11/13/2002	11/13/2002	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
ADMISSION	ADMISSION	NN	B-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
LEFT	LEFT	NNP	B-NP	O
FOURTH	FOURTH	NNP	I-NP	O
TOE	TOE	NNP	I-NP	O
GANGRENE	GANGRENE	NNP	I-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
49-year-old	49-year-old	JJ	I-NP	O
woman	woman	NN	I-NP	O
with	with	IN	B-PP	O
diabetes	diabete	NNS	B-NP	O
and	and	CC	O	O
well	well	RB	B-VP	O
known	know	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Vascular	Vascular	NNP	I-NP	O
Surgery	Surgery	NNP	I-NP	O
Service	Service	NNP	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	VBD	B-VP	O
multiple	multiple	JJ	B-NP	O
bilateral	bilateral	JJ	I-NP	O
toe	toe	NN	I-NP	O
amputations	amputation	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
last	last	JJ	B-ADJP	O
here	here	RB	B-ADVP	O
in	in	IN	B-PP	O
April	April	NNP	B-NP	O
of	of	IN	B-PP	O
2002	2002	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
on	on	IN	B-PP	O
March	March	NNP	B-NP	O
,	,	,	O	O
2002	2002	CD	B-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
planned	plan	VBN	I-NP	O
left	leave	VBD	B-VP	O
fourth	fourth	JJ	B-NP	O
toe	toe	NN	I-NP	O
amputation	amputation	NN	I-NP	O
and	and	CC	O	O
VAC	VAC	NN	B-NP	O
sponge	sponge	NN	I-NP	O
change	change	NN	I-NP	O
by	by	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Ettel	Ettel	NNP	I-NP	O
PAST	PAST	NNP	I-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
past	past	JJ	I-NP	O
medical	medical	JJ	I-NP	O
history	history	NN	I-NP	O
includes	include	VBZ	B-VP	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
myocardial	myocardial	JJ	I-NP	O
infarction	infarction	NN	I-NP	O
,	,	,	O	O
insulin	insulin	NN	B-NP	B-protein
dependent	dependent	JJ	I-NP	O
diabetes	diabete	NNS	I-NP	O
mellitus	mellitus	NN	I-NP	O
,	,	,	O	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
seizures	seizure	NNS	B-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
cerebrovascular	cerebrovascular	JJ	I-NP	O
accident	accident	NN	I-NP	O
,	,	,	O	O
gastroesophageal	gastroesophageal	JJ	B-NP	O
reflux	reflux	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
asthma	asthma	NN	B-NP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
allergies	allergy	NNS	I-NP	O
include	include	VBP	B-VP	O
penicillin	penicillin	NN	B-NP	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
,	,	,	O	O
NSAIDs	NSAID	NNS	B-NP	O
,	,	,	O	O
and	and	CC	O	O
pentazocine	pentazocine	NN	B-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
ON	ON	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
At	At	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
on	on	IN	B-PP	O
Zestril	Zestril	NNP	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
Plavix	Plavix	NNP	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
Peri-Colace	Peri-Colace	NNP	B-NP	O
30	30	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
Niferex	Niferex	NNP	B-NP	O
150	150	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
Gabitril	Gabitril	NNP	B-NP	O
12	12	CD	I-NP	O
TIT	TIT	NNP	I-NP	O
t.i.d.	t.i.d.	NNP	I-NP	O
,	,	,	O	O
Flagyl	Flagyl	NNP	B-NP	O
500	500	CD	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
,	,	,	O	O
Lantus	Lantus	NNP	B-NP	O
insulin	insulin	NN	I-NP	O
80	80	CD	B-NP	O
units	unit	NNS	I-NP	O
q.h.s.	q.h.s.	NN	B-NP	O
,	,	,	O	O
ceftazidime	ceftazidime	NN	B-NP	B-protein
1	1	CD	I-NP	I-protein
gm	gm	NN	I-NP	I-protein
q.	q.	NN	I-NP	I-protein
8	8	CD	I-NP	I-protein
,	,	,	O	O
vancomycin	vancomycin	NN	B-NP	O
1	1	CD	I-NP	O
gm	gm	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
,	,	,	O	O
esomeprazole	esomeprazole	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
Prozac	Prozac	NNP	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
q.d.	q.d.	RB	B-ADVP	O
,	,	,	O	O
folic	folic	JJ	B-NP	O
acid	acid	NN	I-NP	O
1	1	CD	I-NP	O
mg	mg	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
Humalog	Humalog	NNP	B-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
,	,	,	O	O
Lasix	Lasix	NN	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Dilaudid	Dilaudid	NNP	B-NP	O
p.r.n.	p.r.n.	NNP	I-NP	O
,	,	,	O	O
Dulcolax	Dulcolax	NNP	B-NP	O
p.r.n.	p.r.n.	NNP	I-NP	O
,	,	,	O	O
ofloxacin	ofloxacin	NN	B-NP	O
0.3	0.3	CD	I-NP	O
%	%	NN	I-NP	O
ophthalmologic	ophthalmologic	JJ	B-ADJP	O
drops	drop	VBZ	B-VP	O
one	one	CD	B-NP	O
OU	OU	NNP	I-NP	O
q.i.d.	q.i.d.	NNP	I-NP	O
,	,	,	O	O
Cosopt	Cosopt	NNP	B-NP	O
one	one	CD	I-NP	O
drop	drop	NN	I-NP	O
OU	OU	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
,	,	,	O	O
brimonidine	brimonidine	NN	B-NP	O
tartrate	tartrate	NN	I-NP	O
0.2	0.2	CD	B-NP	O
%	%	NN	I-NP	O
ophthalmologic	ophthalmologic	JJ	B-ADJP	O
drops	drop	VBZ	B-VP	O
one	one	CD	B-NP	O
OU	OU	NNP	I-NP	O
q.i.d.	q.i.d.	NNP	I-NP	O
,	,	,	O	O
Pred	Pred	NNP	B-NP	O
Forte	Forte	NNP	I-NP	O
0.12	0.12	CD	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
drops	drop	VBZ	B-VP	O
both	both	DT	B-NP	O
eyes	eye	NNS	I-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	JJ	B-NP	O
EXAMINATION	EXAMINATION	NN	I-NP	O
:	:	:	O	O
Physical	Physical	JJ	B-NP	O
examination	examination	NN	I-NP	O
revealed	reveal	VBD	B-VP	O
temperature	temperature	NN	B-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
98.7	98.7	CD	B-NP	O
,	,	,	O	O
heart	heart	NN	B-NP	O
rate	rate	NN	I-NP	O
72	72	CD	I-NP	O
,	,	,	O	O
and	and	CC	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
154/71	154/71	CD	I-NP	O
.	.	.	O	O

HEENT	HEENT	NN	B-NP	B-protein
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
chest	chest	NN	I-NP	O
was	be	VBD	B-VP	O
clear	clear	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
abdomen	abdomen	NN	I-NP	O
was	be	VBD	B-VP	O
protuberant	protuberant	JJ	B-ADJP	O
,	,	,	O	O
soft	soft	JJ	B-ADJP	O
,	,	,	O	O
and	and	CC	O	O
non-tender	non-tender	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
extremities	extremity	NNS	I-NP	O
revealed	reveal	VBD	B-VP	O
open	open	JJ	B-NP	O
amputations	amputation	NNS	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
bilateral	bilateral	JJ	I-NP	O
feet	foot	NNS	I-NP	O
with	with	IN	B-PP	O
2	2	CD	B-NP	O
+	+	SYM	I-NP	O
femoral	femoral	JJ	I-NP	O
pulses	pulse	NNS	I-NP	O
and	and	CC	O	O
palpable	palpable	JJ	B-NP	O
DP	DP	NN	I-NP	O
and	and	CC	I-NP	O
PT	PT	NN	I-NP	O
pulses	pulse	NNS	I-NP	O
bilaterally	bilaterally	RB	B-ADVP	O
with	with	IN	B-PP	O
right	right	RB	B-ADVP	O
greater	great	JJR	I-ADVP	O
than	than	IN	B-PP	O
left	left	JJ	B-ADJP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
cellulitis	cellulitis	NN	B-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
necrotic	necrotic	JJ	I-NP	O
left	left	JJ	I-NP	O
fourth	fourth	JJ	I-NP	O
toe	toe	NN	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	NNP	B-NP	O
COURSE	COURSE	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Vascular	Vascular	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
fourth	fourth	JJ	I-NP	O
toe	toe	NN	I-NP	O
amputation	amputation	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
occurred	occur	VBD	B-VP	O
on	on	IN	B-PP	O
April	April	NNP	B-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
wound	wound	NN	I-NP	O
was	be	VBD	B-VP	O
left	leave	VBN	I-VP	O
open	open	JJ	B-ADJP	O
.	.	.	O	O

She	She	PRP	B-NP	O
tolerated	tolerate	VBD	B-VP	O
the	the	DT	B-NP	O
procedure	procedure	NN	I-NP	O
well	well	RB	B-ADVP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
VAC	VAC	NN	I-NP	O
change	change	NN	I-NP	O
occurring	occur	VBG	B-VP	O
on	on	IN	B-PP	O
August	August	NNP	B-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
bedside	bedside	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
that	that	IN	B-SBAR	O
,	,	,	O	O
although	although	IN	B-SBAR	O
,	,	,	O	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
pink	pink	JJ	B-NP	O
granulation	granulation	NN	I-NP	O
tissue	tissue	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
fifth	fifth	JJ	I-NP	O
toe	toe	NN	I-NP	O
had	have	VBD	B-VP	O
become	become	VBN	I-VP	O
ischemic	ischemic	JJ	B-ADJP	O
and	and	CC	I-ADJP	O
nonviable	nonviable	JJ	I-ADJP	O
.	.	.	O	O

Therefore	Therefore	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
taken	take	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
operating	operating	NN	I-NP	O
room	room	NN	I-NP	O
on	on	IN	B-PP	O
August	August	NNP	B-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
left	left	JJ	I-NP	O
fifth	fifth	JJ	I-NP	O
toe	toe	NN	I-NP	O
amputation	amputation	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
left	leave	VBN	I-VP	O
open	open	JJ	B-ADJP	O
.	.	.	O	O

That	That	DT	B-NP	O
was	be	VBD	B-VP	O
tolerated	tolerate	VBN	I-VP	O
well	well	RB	B-ADVP	O
,	,	,	O	O
but	but	CC	O	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
seem	seem	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
viable	viable	JJ	B-ADJP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
ischemia	ischemia	NN	B-NP	O
and	and	CC	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

Therefore	Therefore	RB	B-ADVP	O
,	,	,	O	O
on	on	IN	B-PP	O
March	March	NNP	B-NP	O
,	,	,	O	O
2002	2002	CD	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
taken	take	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
operating	operating	NN	I-NP	O
room	room	NN	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
left	left	JJ	I-NP	O
transmetatarsal	transmetatarsal	JJ	I-NP	O
amputation	amputation	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
third	third	JJ	I-NP	O
,	,	,	I-NP	O
fourth	fourth	JJ	I-NP	O
and	and	CC	I-NP	O
fifth	fifth	JJ	I-NP	O
toes	toe	NNS	I-NP	O
.	.	.	O	O

Dressing	Dress	VBG	B-NP	O
changes	change	NNS	I-NP	O
,	,	,	O	O
wet-to-dry	wet-to-dry	JJ	B-ADJP	O
,	,	,	O	O
were	be	VBD	B-VP	O
done	do	VBN	I-VP	O
.	.	.	O	O

During	During	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
that	that	IN	B-SBAR	O
additional	additional	JJ	B-NP	O
necrotic	necrotic	JJ	I-NP	O
debris	debris	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
lateral	lateral	JJ	I-NP	O
aspect	aspect	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
foot	foot	NN	I-NP	O
required	require	VBD	B-VP	O
more	more	JJR	B-NP	O
debridement	debridement	NN	I-NP	O
,	,	,	O	O
so	so	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
taken	take	VBN	I-VP	O
to	to	TO	B-PP	O
surgery	surgery	NN	B-NP	O
on	on	IN	B-PP	O
April	April	NNP	B-NP	O
for	for	IN	B-PP	O
debridement	debridement	NN	B-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
partial	partial	JJ	I-NP	O
resection	resection	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
fifth	fifth	JJ	I-NP	O
metatarsal	metatarsal	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
VAC	VAC	NN	I-NP	B-protein
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
and	and	CC	O	O
changed	change	VBN	B-VP	O
on	on	IN	B-PP	O
March	March	NNP	B-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
bedside	bedside	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
October	October	NNP	B-NP	O
,	,	,	O	O
2002	2002	CD	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
wound	wound	NN	I-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
clean	clean	JJ	B-ADJP	O
enough	enough	RB	I-ADJP	O
and	and	CC	O	O
a	a	DT	B-NP	O
split	split	JJ	I-NP	O
thickness	thickness	NN	I-NP	O
skin	skin	NN	I-NP	O
graft	graft	NN	I-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
,	,	,	O	O
75	75	CD	B-NP	O
square	square	JJ	I-NP	O
cm	cm	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
the	the	DT	B-NP	O
donor	donor	NN	I-NP	B-DNA
site	site	NN	I-NP	I-DNA
was	be	VBD	B-VP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
thigh	thigh	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
seemed	seem	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
taking	take	VBG	I-VP	O
well	well	RB	B-ADVP	O
.	.	.	O	O

We	We	PRP	B-NP	O
continued	continue	VBD	B-VP	O
with	with	IN	B-PP	O
dressing	dress	VBG	B-NP	O
changes	change	NNS	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
heat	heat	NN	I-NP	O
lamp	lamp	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
donor	donor	NN	I-NP	B-DNA
site	site	NN	I-NP	I-DNA
,	,	,	O	O
which	which	WDT	B-NP	O
healed	heal	VBD	B-VP	O
well	well	RB	B-ADVP	O
.	.	.	O	O

On	On	IN	B-PP	O
February	February	NNP	B-NP	O
,	,	,	O	O
2002	2002	CD	B-NP	O
,	,	,	O	O
we	we	PRP	B-NP	O
took	take	VBD	B-VP	O
her	her	PRP	B-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
operating	operating	NN	I-NP	O
room	room	NN	I-NP	O
again	again	RB	B-ADVP	O
for	for	IN	B-PP	O
debridement	debridement	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
plantar	plantar	NN	I-NP	O
aspect	aspect	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
skin	skin	NN	I-NP	O
graft	graft	NN	I-NP	O
had	have	VBD	B-VP	O
become	become	VBN	I-VP	O
discolored	discolor	VBN	I-VP	O
and	and	CC	O	O
we	we	PRP	B-NP	O
felt	feel	VBD	B-VP	O
the	the	DT	B-NP	O
infection	infection	NN	I-NP	O
required	require	VBD	B-VP	O
debridement	debridement	NN	B-NP	O
.	.	.	O	O

Intraoperatively	Intraoperatively	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
bone	bone	NN	I-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
seem	seem	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
involved	involve	VBN	I-VP	O
and	and	CC	O	O
,	,	,	O	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
we	we	PRP	B-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
continuing	continue	VBG	I-VP	O
wet-to-dry	wet-to-dry	JJ	B-NP	O
dressing	dress	VBG	I-NP	O
changes	change	NNS	I-NP	O
and	and	CC	O	O
,	,	,	O	O
as	as	IN	B-PP	O
of	of	IN	B-PP	O
January	January	NNP	B-NP	O
,	,	,	O	O
2002	2002	CD	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
plan	plan	NN	I-NP	O
was	be	VBD	B-VP	O
to	to	TO	B-VP	O
take	take	VB	I-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
operating	operating	NN	I-NP	O
room	room	NN	I-NP	O
on	on	IN	B-PP	O
January	January	NNP	B-NP	O
,	,	,	O	O
2002	2002	CD	B-NP	O
for	for	IN	B-PP	O
another	another	DT	B-NP	O
skin	skin	NN	I-NP	O
graft	graft	NN	I-NP	O
.	.	.	O	O

Now	Now	RB	B-ADVP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
wound	wound	NN	I-NP	O
is	be	VBZ	B-VP	O
clean	clean	JJ	B-ADJP	O
,	,	,	O	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
completed	complete	VBN	I-VP	O
antibiotics	antibiotic	NNS	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Neurological	Neurological	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
seizure	seizure	NN	I-NP	O
disorder	disorder	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
stable	stable	JJ	B-ADJP	O
on	on	IN	B-PP	O
Gabitril	Gabitril	NNP	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
stroke	stroke	NN	I-NP	O
and	and	CC	O	O
is	be	VBZ	B-VP	O
stable	stable	JJ	B-ADJP	O
.	.	.	O	O

For	For	IN	B-PP	O
her	her	PRP$	B-NP	O
depression	depression	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
receives	receive	VBZ	B-VP	O
Prozac	Prozac	NNP	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
pain	pain	NN	I-NP	O
is	be	VBZ	B-VP	O
well	well	RB	I-VP	O
controlled	control	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
Fentanyl	Fentanyl	NN	I-NP	O
patch	patch	NN	I-NP	O
with	with	IN	B-PP	O
oxycodone	oxycodone	NN	B-NP	O
for	for	IN	B-PP	O
p.r.n.	p.r.n.	NN	B-NP	O
pain	pain	NN	I-NP	O
and	and	CC	I-NP	O
Dilaudid	Dilaudid	NN	I-NP	O
for	for	IN	B-PP	O
breakthrough	breakthrough	NN	B-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
also	also	RB	B-ADVP	O
has	have	VBZ	B-VP	O
occasional	occasional	JJ	B-NP	O
dizziness	dizziness	NN	I-NP	O
and	and	CC	O	O
this	this	DT	B-NP	O
is	be	VBZ	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
p.r.n.	p.r.n.	NN	B-NP	O
meclizine	meclizine	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
is	be	VBZ	B-VP	O
status	status	NN	B-NP	O
post	post	IN	B-PP	O
a	a	DT	B-NP	O
myocardial	myocardial	JJ	I-NP	O
infarction	infarction	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
currently	currently	RB	I-VP	O
well	well	RB	I-VP	O
controlled	control	VBN	I-VP	O
on	on	IN	B-PP	O
Lopressor	Lopressor	NN	B-NP	B-protein
50	50	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
t.i.d.	t.i.d.	NN	I-NP	I-protein
4	4	CD	I-NP	I-protein
.	.	.	O	O

Respiratory	Respiratory	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
asthma	asthma	NN	B-NP	O
that	that	WDT	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
stable	stable	JJ	B-ADJP	O
and	and	CC	O	O
not	not	RB	B-VP	O
evidenced	evidence	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
hospital	hospital	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

GI	GI	LS	B-LST	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
gastroesophageal	gastroesophageal	JJ	B-NP	O
reflux	reflux	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
esomeprazole	esomeprazole	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
diabetic	diabetic	JJ	I-NP	O
diet	diet	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
receives	receive	VBZ	B-VP	O
Colace	Colace	NNP	B-NP	O
,	,	,	O	O
Senna	Senna	NNP	B-NP	O
,	,	,	O	O
multivitamins	multivitamin	NNS	B-NP	O
,	,	,	O	O
folic	folic	JJ	B-NP	O
acid	acid	NN	I-NP	O
and	and	CC	I-NP	O
Niferex	Niferex	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

GU	GU	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
receiving	receive	VBG	I-VP	O
Lasix	Lasix	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
moment	moment	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
admission	admission	NN	I-NP	O
creatinine	creatinine	NN	I-NP	O
was	be	VBD	B-VP	O
0.7	0.7	CD	B-NP	O
,	,	,	O	O
peaked	peak	VBD	B-VP	O
at	at	IN	B-PP	O
2.0	2.0	CD	B-NP	O
on	on	IN	B-PP	O
February	February	NNP	B-NP	O
,	,	,	O	O
at	at	IN	B-PP	O
which	which	WDT	B-NP	O
time	time	NN	I-NP	O
we	we	PRP	B-NP	O
called	call	VBD	B-VP	O
a	a	DT	B-NP	O
renal	renal	JJ	I-NP	O
consultation	consultation	NN	I-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
said	say	VBD	B-VP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
probably	probably	RB	B-ADVP	O
pre-renal	pre-renal	JJ	B-NP	O
acute	acute	JJ	I-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-VP	O
ace	ace	VB	I-VP	O
inhibitor	inhibitor	NN	B-NP	O
,	,	,	O	O
Lasix	Lasix	NNP	B-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
new	new	JJ	I-NP	O
bunch	bunch	NN	I-NP	O
of	of	IN	B-PP	O
antibiotics	antibiotic	NNS	B-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
we	we	PRP	B-NP	O
held	hold	VBD	B-VP	O
the	the	DT	B-NP	O
ace	ace	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
,	,	,	O	O
held	hold	VBD	B-VP	O
the	the	DT	B-NP	O
Lasix	Lasix	NNP	I-NP	O
,	,	,	O	O
and	and	CC	O	O
renally	renally	RB	B-VP	O
dosed	dose	VBD	I-VP	O
the	the	DT	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
,	,	,	O	O
at	at	IN	B-PP	O
which	which	WDT	B-NP	O
time	time	NN	I-NP	O
her	her	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
came	come	VBD	B-VP	O
down	down	RB	B-ADVP	O
to	to	TO	B-PP	O
1.1	1.1	CD	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
closer	close	JJR	B-ADJP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
baseline	baseline	NN	I-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
have	have	VBP	B-VP	O
slowly	slowly	RB	I-VP	O
restarted	restart	VBN	I-VP	O
Lasix	Lasix	NN	B-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
tolerated	tolerate	VBN	I-VP	O
that	that	IN	B-SBAR	O
.	.	.	O	O

We	We	PRP	B-NP	O
have	have	VBP	B-VP	O
since	since	IN	I-VP	O
discontinued	discontinue	VBN	I-VP	O
her	her	PRP$	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Heme	Heme	NN	B-NP	B-protein
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
admission	admission	NN	I-NP	O
hematocrit	hematocrit	NN	I-NP	O
was	be	VBD	B-VP	O
25.7	25.7	CD	B-NP	O
,	,	,	O	O
for	for	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
received	receive	VBD	B-VP	O
1	1	CD	B-NP	O
unit	unit	NN	I-NP	O
of	of	IN	B-PP	O
packed	packed	JJ	B-NP	B-cell_type
red	red	JJ	I-NP	I-cell_type
blood	blood	NN	I-NP	I-cell_type
cells	cell	NNS	I-NP	I-cell_type
on	on	IN	B-PP	O
April	April	NNP	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
received	receive	VBD	B-VP	O
another	another	DT	B-NP	O
unit	unit	NN	I-NP	O
of	of	IN	B-PP	O
packed	packed	JJ	B-NP	B-cell_type
red	red	JJ	I-NP	I-cell_type
blood	blood	NN	I-NP	I-cell_type
cells	cell	NNS	I-NP	I-cell_type
on	on	IN	B-PP	O
November	November	NNP	B-NP	O
and	and	CC	O	O
her	her	PRP	B-NP	O
most	most	RBS	I-NP	O
recent	recent	JJ	I-NP	O
hematocrit	hematocrit	NN	I-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
January	January	NNP	B-NP	O
,	,	,	O	O
was	be	VBD	B-VP	O
26.8	26.8	CD	B-NP	O
.	.	.	O	O

Therefore	Therefore	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
is	be	VBZ	B-VP	O
baseline	baseline	NN	B-NP	O
anemic	anemic	JJ	B-ADJP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
Disease	Disease	NN	I-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
another	another	DT	B-NP	O
major	major	JJ	I-NP	O
issue	issue	NN	I-NP	O
for	for	IN	B-PP	O
this	this	DT	B-NP	O
patient	patient	NN	I-NP	O
.	.	.	O	O

Starting	Start	VBG	B-VP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
beginning	beginning	NN	I-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
October	October	NNP	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
urinary	urinary	JJ	I-NP	O
tract	tract	NN	I-NP	O
infection	infection	NN	I-NP	O
with	with	IN	B-PP	O
mixed	mix	VBN	B-NP	O
flora	flora	NN	I-NP	O
,	,	,	O	O
for	for	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
five	five	CD	I-NP	O
day	day	NN	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
Diflucan	Diflucan	NNP	B-NP	O
for	for	IN	B-PP	O
Candida	Candida	NNP	B-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
April	April	NNP	B-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
wound	wound	JJ	I-NP	O
culture	culture	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
showed	show	VBD	B-VP	O
Pseudomonas	Pseudomonas	NNP	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
resistant	resistant	JJ	B-ADJP	O
to	to	TO	B-PP	O
multiple	multiple	JJ	B-NP	O
drugs	drug	NNS	I-NP	O
,	,	,	O	O
multidrug	multidrug	JJ	B-NP	O
resistant	resistant	JJ	I-NP	O
E.	E.	NNP	I-NP	O
coli	coli	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
methicillin	methicillin	NN	B-NP	O
resistant	resistant	JJ	I-NP	O
Staphylococcus	Staphylococcus	NNP	I-NP	O
aureus	aureus	NN	I-NP	O
,	,	,	O	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
multidrug	multidrug	JJ	B-NP	O
resistant	resistant	JJ	I-NP	O
Klebsiella	Klebsiella	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
February	February	NNP	B-NP	O
,	,	,	O	O
when	when	WRB	B-ADVP	O
we	we	PRP	B-NP	O
went	go	VBD	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
operating	operating	NN	I-NP	O
room	room	NN	I-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
debridement	debridement	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
,	,	,	O	O
we	we	PRP	B-NP	O
obtained	obtain	VBD	B-VP	O
deep	deep	JJ	B-NP	O
cultures	culture	NNS	I-NP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
operating	operating	NN	I-NP	O
room	room	NN	I-NP	O
and	and	CC	O	O
found	find	VBN	B-VP	O
Pseudomonas	Pseudomonas	NNP	B-NP	O
diphtheroid	diphtheroid	NN	I-NP	O
and	and	CC	I-NP	O
Klebsiella	Klebsiella	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
were	be	VBD	B-VP	O
sensitive	sensitive	JJ	B-ADJP	O
to	to	TO	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
and	and	CC	I-NP	O
cefotaxime	cefotaxime	NN	I-NP	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
Disease	Disease	NN	I-NP	O
had	have	VBD	B-VP	O
consulted	consult	VBN	I-VP	O
on	on	IN	B-PP	O
our	our	PRP$	B-NP	O
patient	patient	NN	I-NP	O
and	and	CC	O	O
recommended	recommend	VBD	B-VP	O
vancomycin	vancomycin	NN	B-NP	O
,	,	,	I-NP	O
cefepime	cefepime	NN	I-NP	O
and	and	CC	I-NP	O
Flagyl	Flagyl	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
two	two	CD	I-NP	O
week	week	NN	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
these	these	DT	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
soft	soft	JJ	I-NP	O
tissue	tissue	NN	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
appear	appear	VB	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
operating	operating	NN	I-NP	O
room	room	NN	I-NP	O
again	again	RB	B-ADVP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
bone	bone	NN	I-NP	O
was	be	VBD	B-VP	O
involved	involve	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
MRI	MRI	NNP	I-NP	O
on	on	IN	B-PP	O
August	August	NNP	B-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
showed	show	VBD	B-VP	O
soft	soft	JJ	B-NP	O
tissue	tissue	NN	I-NP	O
swelling	swell	VBG	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
sinus	sinus	NN	I-NP	O
tract	tract	NN	I-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
suspicious	suspicious	JJ	B-ADJP	O
for	for	IN	B-PP	O
osteomyelitis	osteomyelitis	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
fifth	fifth	JJ	I-NP	O
metatarsal	metatarsal	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
,	,	,	O	O
in	in	IN	B-PP	O
consultation	consultation	NN	B-NP	O
with	with	IN	B-PP	O
Infectious	Infectious	JJ	B-NP	O
Disease	Disease	NN	I-NP	O
,	,	,	O	O
Vascular	Vascular	NNP	B-NP	O
Surgery	Surgery	NNP	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
operative	operative	JJ	I-NP	O
findings	finding	NNS	I-NP	O
,	,	,	O	O
and	and	CC	O	O
clinical	clinical	JJ	B-NP	O
picture	picture	NN	I-NP	O
,	,	,	O	O
we	we	PRP	B-NP	O
decided	decide	VBD	B-VP	O
it	it	PRP	B-NP	O
looked	look	VBD	B-VP	O
more	more	JJR	B-ADVP	O
like	like	IN	B-PP	O
a	a	DT	B-NP	O
soft	soft	JJ	I-NP	O
tissue	tissue	NN	I-NP	O
infection	infection	NN	I-NP	O
and	and	CC	O	O
treated	treat	VBN	B-VP	O
her	her	PRP	B-NP	O
for	for	IN	B-PP	O
two	two	CD	B-NP	O
weeks	week	NNS	I-NP	O
with	with	IN	B-PP	O
antibiotics	antibiotic	NNS	B-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Endocrine	Endocrine	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
diabetes	diabete	NNS	B-NP	O
mellitus	mellitus	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
sugar	sugar	NN	I-NP	O
control	control	NN	I-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
an	an	DT	B-NP	O
issue	issue	NN	I-NP	O
throughout	throughout	IN	B-PP	O
her	her	PRP$	B-NP	O
hospital	hospital	NN	I-NP	O
stay	stay	NN	I-NP	O
,	,	,	O	O
slowly	slowly	RB	B-VP	O
titrating	titrate	VBG	I-VP	O
up	up	RP	B-PRT	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
current	current	JJ	I-NP	O
Lantus	Lantus	NNP	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
150	150	CD	B-NP	O
units	unit	NNS	I-NP	O
subq	subq	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
seems	seem	VBZ	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
doing	do	VBG	I-VP	O
well	well	RB	B-ADVP	O
with	with	IN	B-PP	O
that	that	DT	B-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Ophthalmology	Ophthalmology	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
bilateral	bilateral	JJ	I-NP	O
cataract	cataract	NN	I-NP	O
surgery	surgery	NN	I-NP	O
and	and	CC	O	O
attempted	attempt	VBN	B-NP	O
filter	filter	NN	I-NP	O
for	for	IN	B-PP	O
glaucoma	glaucoma	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
eye	eye	NN	I-NP	O
and	and	CC	O	O
high	high	JJ	B-NP	O
pressure	pressure	NN	I-NP	O
with	with	IN	B-PP	O
pain	pain	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
proliferative	proliferative	JJ	B-NP	O
retinopathy	retinopathy	NN	I-NP	O
with	with	IN	B-PP	O
bilateral	bilateral	JJ	B-NP	O
traction	traction	NN	I-NP	O
detachment	detachment	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
taking	take	VBG	I-VP	O
the	the	DT	B-NP	O
following	follow	VBG	I-NP	O
medications	medication	NNS	I-NP	O
:	:	:	O	O
Pred	Pred	NNP	B-NP	O
Forte	Forte	NNP	I-NP	O
,	,	,	O	O
Cosopt	Cosopt	NNP	B-NP	O
,	,	,	O	O
ofloxacin	ofloxacin	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Alphagan	Alphagan	NNP	B-NP	O
for	for	IN	B-PP	O
her	her	PRP$	B-NP	O
eyes	eye	NNS	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
August	August	NNP	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
Ophthalmology	Ophthalmology	NNP	I-NP	O
appointment	appointment	NN	I-NP	O
for	for	IN	B-PP	O
floaters	floater	NNS	B-NP	O
and	and	CC	O	O
that	that	IN	B-SBAR	O
diagnosis	diagnosis	NN	B-NP	O
was	be	VBD	B-VP	O
proliferative	proliferative	JJ	B-NP	O
diabetic	diabetic	JJ	I-NP	O
retinopathy	retinopathy	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
pan	pan	NN	I-NP	O
retinal	retinal	JJ	I-NP	O
phototherapy	phototherapy	NN	I-NP	O
with	with	IN	B-PP	O
vitreous	vitreous	JJ	B-NP	O
hemorrhage	hemorrhage	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
October	October	NNP	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
appointment	appointment	NN	I-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Saulsbury	Saulsbury	NNP	I-NP	O
at	at	IN	B-PP	O
277-598-1768	277-598-1768	CD	B-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
recommended	recommend	VBD	B-VP	O
to	to	TO	I-VP	O
add	add	VB	I-VP	O
timolol	timolol	NN	B-NP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
eye	eye	NN	I-NP	O
drops	drop	NNS	I-NP	O
,	,	,	O	O
and	and	CC	O	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
following	follow	VBG	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
her	her	PRP	B-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Dental	Dental	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
appointment	appointment	NN	I-NP	O
on	on	IN	B-PP	O
July	July	NNP	B-NP	O
,	,	,	O	O
where	where	WRB	B-ADVP	O
they	they	PRP	B-NP	O
recommended	recommend	VBD	B-VP	O
a	a	DT	B-NP	O
root	root	NN	I-NP	O
canal	canal	NN	I-NP	O
of	of	IN	B-PP	O
#	#	#	B-NP	B-DNA
18	18	CD	I-NP	I-DNA
and	and	CC	O	I-DNA
#	#	#	B-NP	I-DNA
19	19	CD	I-NP	I-DNA
for	for	IN	B-PP	O
caries	cary	NNS	B-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
root	root	NN	I-NP	O
canal	canal	NN	I-NP	O
was	be	VBD	B-VP	O
done	do	VBN	I-VP	O
on	on	IN	B-PP	O
January	January	NNP	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
number	number	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
clinic	clinic	NN	I-NP	O
is	be	VBZ	B-VP	O
210-793-1150	210-793-1150	CD	B-NP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Skin	Skin	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
received	receive	VBD	B-VP	O
Lotrimin	Lotrimin	NN	B-NP	O
,	,	,	I-NP	O
miconazole	miconazole	NN	I-NP	O
and	and	CC	I-NP	O
wound	wound	NN	I-NP	O
care	care	NN	I-NP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
foot	foot	NN	I-NP	O
with	with	IN	B-PP	O
Regranex	Regranex	NNP	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
is	be	VBZ	B-VP	O
receiving	receive	VBG	I-VP	O
wet-to-dries	wet-to-dry	NNS	B-NP	O
q.d.	q.d.	RB	B-ADVP	O
13	13	CD	B-NP	O
.	.	.	O	O

Tubes	Tube	NNS	B-NP	O
,	,	,	I-NP	O
lines	line	NNS	I-NP	O
and	and	CC	I-NP	O
drains	drain	NNS	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	B-cell_line
PICC	PICC	NN	I-NP	I-cell_line
line	line	NN	I-NP	I-cell_line
placed	place	VBN	B-VP	O
on	on	IN	B-PP	O
October	October	NNP	B-NP	O
,	,	,	O	O
2002	2002	CD	B-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
INSTRUCTIONS	INSTRUCTIONS	NNS	I-NP	O
:	:	:	O	O
Neurological	Neurological	JJ	B-ADJP	O
:	:	:	O	O
Continue	Continue	NNP	B-NP	O
.	.	.	O	O

Cardiac	Cardiac	NNP	B-NP	O
:	:	:	O	O
Continue	Continue	NNP	B-NP	O
.	.	.	O	O

Respiratory	Respiratory	NNP	B-NP	O
:	:	:	O	O
Continue	Continue	NNP	B-NP	O
.	.	.	O	O

GI	GI	LS	B-LST	O
:	:	:	O	O
Continue	Continue	VB	B-VP	O
.	.	.	O	O

GU	GU	NN	B-NP	O
:	:	:	O	O
Continue	Continue	NN	B-NP	O
with	with	IN	B-PP	O
monitoring	monitoring	NN	B-NP	O
of	of	IN	B-PP	O
creatinine	creatinine	NN	B-NP	O
.	.	.	O	O

Heme	Heme	NNP	B-NP	B-protein
:	:	:	O	O
Continue	Continue	NNP	B-NP	O
with	with	IN	B-PP	O
monitoring	monitoring	NN	B-NP	O
of	of	IN	B-PP	O
hospital	hospital	NN	B-NP	O
course	course	NN	I-NP	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
Disease	Disease	NN	I-NP	O
:	:	:	O	O
No	No	DT	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
needed	need	VBD	B-VP	O
,	,	,	O	O
but	but	CC	O	O
follow	follow	NN	B-NP	O
left	leave	VBD	B-VP	O
wound	wound	NN	B-NP	O
closely	closely	RB	B-ADVP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
is	be	VBZ	B-VP	O
positive	positive	JJ	B-ADJP	O
for	for	IN	B-PP	O
methicillin	methicillin	NN	B-NP	O
resistant	resistant	JJ	I-NP	O
Staphylococcus	Staphylococcus	NNP	I-NP	O
aureus	aureus	NN	I-NP	O
,	,	,	O	O
so	so	IN	B-SBAR	O
she	she	PRP	B-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
in	in	IN	B-PP	O
isolation	isolation	NN	B-NP	O
.	.	.	O	O

Endocrine	Endocrine	JJ	B-ADJP	O
:	:	:	O	O
Blood	Blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
control	control	NN	I-NP	O
.	.	.	O	O

Ophthalmology	Ophthalmology	NN	B-NP	O
:	:	:	O	O
She	She	PRP	B-NP	O
need	need	VBP	B-VP	O
follow-up	follow-up	NN	B-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
ophthalmologist	ophthalmologist	NN	I-NP	O
about	about	IN	B-PP	O
her	her	PRP$	B-NP	O
retinopathy	retinopathy	NN	I-NP	O
,	,	,	O	O
bilateral	bilateral	JJ	B-NP	O
detachment	detachment	NN	I-NP	O
and	and	CC	I-NP	O
glaucoma	glaucoma	NN	I-NP	O
.	.	.	O	O

Dental	Dental	NNP	B-NP	O
:	:	:	O	O
She	She	NNP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
root	root	NN	I-NP	O
canal	canal	NN	I-NP	O
done	do	VBN	B-VP	O
and	and	CC	O	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
follow-up	follow-up	NN	B-NP	O
.	.	.	O	O

Vascular	Vascular	NNP	B-NP	O
:	:	:	O	O
Will	Will	NNP	B-NP	O
need	need	VBP	B-VP	O
to	to	TO	I-VP	O
follow	follow	VB	I-VP	O
her	her	PRP$	B-NP	O
bilateral	bilateral	JJ	I-NP	O
extremity	extremity	NN	I-NP	O
examination	examination	NN	I-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
skin	skin	NN	I-NP	O
graft	graft	NN	I-NP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
to	to	TO	B-VP	O
ensure	ensure	VB	I-VP	O
proper	proper	JJ	B-NP	O
healing	healing	NN	I-NP	O
.	.	.	O	O

As	As	RB	B-ADVP	O
well	well	RB	I-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
needing	need	VBG	I-VP	O
rehabilitation	rehabilitation	NN	B-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
weakness	weakness	NN	B-NP	O
and	and	CC	O	O
decreased	decrease	VBD	B-VP	O
mobility	mobility	NN	B-NP	O
after	after	IN	B-PP	O
these	these	DT	B-NP	O
amputations	amputation	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
heel	heel	JJ	B-NP	O
weight	weight	NN	I-NP	O
bearing	bear	VBG	B-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
left	left	NN	I-NP	O
,	,	,	O	O
weight	weight	NN	B-NP	O
bearing	bear	VBG	B-VP	O
as	as	IN	B-SBAR	O
tolerated	tolerate	VBN	B-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
right	right	NN	I-NP	O
.	.	.	O	O

Goals	Goal	NNS	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
to	to	TO	B-VP	O
have	have	VB	I-VP	O
bed	bed	VBN	I-VP	O
mobility	mobility	NN	B-NP	O
,	,	,	O	O
transfers	transfer	NNS	B-NP	O
,	,	,	O	O
daily	daily	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
with	with	IN	B-PP	O
exercise	exercise	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
the	the	DT	B-NP	O
goal	goal	NN	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
to	to	TO	B-VP	O
ambulate	ambulate	VB	I-VP	O
25	25	CD	B-NP	O
feet	foot	NNS	I-NP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
least	least	JJS	I-NP	O
restrictive	restrictive	JJ	I-NP	O
device	device	NN	I-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
ON	ON	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
At	At	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
actively	actively	RB	B-ADVP	O
on	on	IN	B-PP	O
,	,	,	O	O
as	as	IN	B-PP	O
of	of	IN	B-PP	O
January	January	NNP	B-NP	O
,	,	,	O	O
Lotrimin	Lotrimin	NNP	B-NP	O
topical	topical	JJ	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
,	,	,	O	O
Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
Fentanyl	Fentanyl	NN	B-NP	O
150	150	CD	I-NP	O
mcg	mcg	NN	I-NP	O
q.	q.	NN	I-NP	O
72	72	CD	B-NP	O
hours	hour	NNS	I-NP	O
,	,	,	O	O
Prozac	Prozac	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
q.d.	q.d.	RB	B-ADVP	O
,	,	,	O	O
folic	folic	JJ	B-NP	O
acid	acid	NN	I-NP	O
1	1	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
q.d.	q.d.	FW	I-ADVP	O
,	,	,	O	O
Lasix	Lasix	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
heparin	heparin	NN	B-NP	O
5000	5000	CD	I-NP	O
units	unit	NNS	I-NP	O
subq	subq	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
,	,	,	O	O
insulin	insulin	NN	B-NP	B-protein
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
,	,	,	O	O
Lopressor	Lopressor	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
,	,	,	O	O
Niferex	Niferex	NNP	B-NP	O
150	150	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Pred	Pred	NNP	B-NP	O
Forte	Forte	NNP	I-NP	O
one	one	CD	I-NP	O
drop	drop	NN	I-NP	O
OU	OU	NN	I-NP	O
q.i.d.	q.i.d.	NN	I-NP	O
,	,	,	O	O
Senna	Senna	NNP	B-NP	O
two	two	CD	I-NP	O
tablets	tablet	NNS	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.h.s.	q.h.s.	FW	I-NP	O
,	,	,	O	O
Gabitril	Gabitril	NNP	B-NP	O
12	12	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
miconazole	miconazole	NN	B-NP	O
powder	powder	NN	I-NP	O
to	to	TO	B-PP	O
groin	groin	NN	B-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
,	,	,	O	O
Regranex	Regranex	NNP	B-NP	O
topical	topical	JJ	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
to	to	TO	B-PP	O
right	right	JJ	B-NP	O
foot	foot	NN	I-NP	O
and	and	CC	I-NP	O
cover	cover	NN	I-NP	O
with	with	IN	B-PP	O
loose	loose	JJ	B-NP	O
sterile	sterile	JJ	I-NP	O
dressing	dressing	NN	I-NP	O
,	,	,	O	O
Plavix	Plavix	NN	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
q.d.	q.d.	FW	I-ADVP	O
,	,	,	O	O
Cosopt	Cosopt	NNP	B-NP	O
one	one	CD	I-NP	O
drop	drop	NN	I-NP	O
OU	OU	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
,	,	,	O	O
ofloxacin	ofloxacin	NN	B-NP	O
0.3	0.3	CD	B-NP	O
%	%	NN	I-NP	O
ophthalmologic	ophthalmologic	JJ	I-NP	O
solution	solution	NN	I-NP	O
one	one	CD	B-NP	O
drop	drop	NN	I-NP	O
OU	OU	NN	I-NP	O
q.i.d.	q.i.d.	NN	I-NP	O
,	,	,	O	O
esomeprazole	esomeprazole	NN	B-NP	O
20	20	CD	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.d.	q.d.	FW	I-NP	O
,	,	,	O	O
Lantus	Lantus	NNP	B-NP	O
150	150	CD	I-NP	O
units	unit	NNS	I-NP	O
subq	subq	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
Alphagan	Alphagan	NNP	B-NP	O
one	one	CD	I-NP	O
drop	drop	NN	I-NP	O
OU	OU	NN	I-NP	O
q.i.d.	q.i.d.	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
currently	currently	RB	I-VP	O
using	use	VBG	I-VP	O
one	one	CD	B-NP	O
touch	touch	NN	I-NP	O
ultra	ultra	JJ	I-NP	O
glucose	glucose	NN	I-NP	O
pen	pen	JJ	I-NP	O
stick	stick	NN	I-NP	O
for	for	IN	B-PP	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
draws	draw	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
gets	get	VBZ	B-VP	O
Tylenol	Tylenol	NN	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
,	,	,	O	O
Natural	Natural	NNP	B-NP	O
Tears	Tears	NNP	I-NP	O
p.r.n.	p.r.n.	NNP	I-NP	O
,	,	,	O	O
Dilaudid	Dilaudid	NNP	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
for	for	IN	B-PP	O
pain	pain	NN	B-NP	O
,	,	,	O	O
Milk	Milk	NNP	B-NP	O
of	of	IN	B-PP	O
Magnesia	Magnesia	NNP	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
,	,	,	O	O
meclizine	meclizine	NN	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
oxycodone	oxycodone	NN	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
FOLLOW-UP	FOLLOW-UP	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
instructed	instruct	VBN	I-VP	O
to	to	TO	I-VP	O
follow-up	follow-up	VB	I-VP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Tata	Tata	NNP	I-NP	O
in	in	IN	B-PP	O
two	two	CD	B-NP	O
weeks	week	NNS	I-NP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
date	date	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

Dictated	Dictate	VBN	B-VP	O
By	By	IN	B-PP	O
:	:	:	O	O
JUDSON	JUDSON	NNP	B-NP	O
JACQUIER	JACQUIER	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
BR069	BR069	NNP	I-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
DAMON	DAMON	NNP	B-NP	O
JANAK	JANAK	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
EA32	EA32	NNP	I-NP	O
AJ254/041664	AJ254/041664	NNP	I-NP	O
Batch	Batch	NNP	I-NP	O
:	:	:	O	O
94589	94589	CD	B-NP	O
Index	Index	NNP	I-NP	O
No	No	NNP	I-NP	O
.	.	.	O	O

TFYQ307K43	TFYQ307K43	NN	B-NP	O
D	D	NN	I-NP	O
:	:	:	O	O
7/23/02	7/23/02	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
7/23/02	7/23/02	CD	B-NP	O

